Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Efficacy and Safety Data of XCOPRI® (cenobamate tablets) CV Published in Neurology
Details : The open-label extension of Study C017 demonstrated high response rates with no new safety signals identified in patients receiving XCOPRI (cenobamate) for up to 4 years.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SK life Science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
Details : Phase 3 clinical trial initiated to evaluate the efficacy and safety of YKP509 (carisbamate) for the treatment of seizures associated with LGS. Carisbamate has also received orphan drug designation from the FDA.
Product Name : YKP509
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XCOPRI® (cenobamate tablets) CV, is an anti-seizure medication (ASM), a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 24, 2022
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Epilepsia Publishes Two Post-hoc Analyses from Long-Term Study of XCOPRI® (Cenobamate Tablets) CV
Details : The results of these two new post-hoc analyses provide evidence of the durable efficacy of XCOPRI, as many patients sustained 90% and 100% reductions of their seizures over the course of the entire maintenance period, lasting up to 40.2 months.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
